Home › Compare › TRYPF vs EQR

TRYPF vs EQR: Dividend Comparison 2026

TRYPF yields 3558.72% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRYPF wins by $2329727088831.44M in total portfolio value
10 years
TRYPF
TRYPF
● Live price
3558.72%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2329727088831.49M
Annual income
$2,207,692,570,087,591,000.00
Full TRYPF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — TRYPF vs EQR

📍 TRYPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRYPFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRYPF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRYPF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRYPF
Annual income on $10K today (after 15% tax)
$302,491.10/yr
After 10yr DRIP, annual income (after tax)
$1,876,538,684,574,452,200.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, TRYPF beats the other by $1,876,538,684,574,447,600.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRYPF + EQR for your $10,000?

TRYPF: 50%EQR: 50%
100% EQR50/50100% TRYPF
Portfolio after 10yr
$1164863544415.77M
Annual income
$1,103,846,285,043,798,100.00/yr
Blended yield
94.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TRYPF
No analyst data
Altman Z
-3902.6
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRYPF buys
0
EQR buys
0
No recent congressional trades found for TRYPF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRYPFEQR
Forward yield3558.72% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$2329727088831.49M ✓$47.8K
Annual income after 10y$2,207,692,570,087,591,000.00 ✓$5,475.61
Total dividends collected$2321360563920.16M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TRYPF vs EQR ($10,000, DRIP)

YearTRYPF PortfolioTRYPF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$366,572$355,871.89$11,380$679.82+$355.2K → TRYPF
2$12,584,066$12,191,834.44$13,014$837.25+$12.57M → TRYPF
3$404,618,364$391,153,413.41$14,961$1,036.20+$404.60M → TRYPF
4$12,187,002,569$11,754,060,918.87$17,297$1,289.22+$12186.99M → TRYPF
5$343,908,630,433$330,868,537,684.68$20,121$1,613.15+$343908.61M → TRYPF
6$9,094,035,633,286$8,726,053,398,722.06$23,561$2,030.84+$9094035.61M → TRYPF
7$225,379,725,862,498$215,649,107,734,881.84$27,783$2,573.54+$225379725.83M → TRYPF
8$5,236,002,075,601,348$4,994,845,768,928,476.00$33,013$3,284.39+$5236002075.57M → TRYPF
9$114,050,952,097,100,620$108,448,429,876,207,180.00$39,547$4,223.51+$114050952097.06M → TRYPF
10$2,329,727,088,831,488,000$2,207,692,570,087,591,000.00$47,791$5,475.61+$2329727088831.44M → TRYPF

TRYPF vs EQR: Complete Analysis 2026

TRYPF — Stock

Tryp Therapeutics Inc., a pharmaceutical company, focuses on identifying and developing compounds for diseases with high unmet medical needs. The company's lead development program is (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 and TRP-8803 for fibromyalgia, phantom limb pain, binge eating disorder, complex regional pain syndrome, and hypothalamic obesity. The company has an agreement with the Calvert Labs to design and execute exploratory studies related to psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was incorporated in 2019 and is based in Kelowna, Canada.

Full TRYPF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TRYPF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRYPF vs SCHDTRYPF vs JEPITRYPF vs OTRYPF vs KOTRYPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.